GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Covetrus Inc (NAS:CVET) » Definitions » ROE %

Covetrus (Covetrus) ROE % : -1.06% (As of Jun. 2022)


View and export this data going back to 2019. Start your Free Trial

What is Covetrus ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Covetrus's annualized net income for the quarter that ended in Jun. 2022 was $-16 Mil. Covetrus's average Total Stockholders Equity over the quarter that ended in Jun. 2022 was $1,517 Mil. Therefore, Covetrus's annualized ROE % for the quarter that ended in Jun. 2022 was -1.06%.

The historical rank and industry rank for Covetrus's ROE % or its related term are showing as below:

CVET's ROE % is not ranked *
in the Medical Distribution industry.
Industry Median: 7.24
* Ranked among companies with meaningful ROE % only.

Covetrus ROE % Historical Data

The historical data trend for Covetrus's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Covetrus ROE % Chart

Covetrus Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
ROE %
Get a 7-Day Free Trial 5.48 7.34 -71.35 -1.36 -3.54

Covetrus Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.21 -1.07 -0.80 -0.53 -1.06

Competitive Comparison of Covetrus's ROE %

For the Medical Distribution subindustry, Covetrus's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Covetrus's ROE % Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Covetrus's ROE % distribution charts can be found below:

* The bar in red indicates where Covetrus's ROE % falls into.



Covetrus ROE % Calculation

Covetrus's annualized ROE % for the fiscal year that ended in Dec. 2021 is calculated as

ROE %=Net Income (A: Dec. 2021 )/( (Total Stockholders Equity (A: Dec. 2020 )+Total Stockholders Equity (A: Dec. 2021 ))/ count )
=-54/( (1537+1511)/ 2 )
=-54/1524
=-3.54 %

Covetrus's annualized ROE % for the quarter that ended in Jun. 2022 is calculated as

ROE %=Net Income (Q: Jun. 2022 )/( (Total Stockholders Equity (Q: Mar. 2022 )+Total Stockholders Equity (Q: Jun. 2022 ))/ count )
=-16/( (1528+1505)/ 2 )
=-16/1516.5
=-1.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jun. 2022) net income data. ROE % is displayed in the 30-year financial page.


Covetrus  (NAS:CVET) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2022 )
=Net Income/Total Stockholders Equity
=-16/1516.5
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-16 / 4868)*(4868 / 3434)*(3434 / 1516.5)
=Net Margin %*Asset Turnover*Equity Multiplier
=-0.33 %*1.4176*2.2644
=ROA %*Equity Multiplier
=-0.47 %*2.2644
=-1.06 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2022 )
=Net Income/Total Stockholders Equity
=-16/1516.5
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-16 / -12) * (-12 / 16) * (16 / 4868) * (4868 / 3434) * (3434 / 1516.5)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.3333 * -0.75 * 0.33 % * 1.4176 * 2.2644
=-1.06 %

Note: The net income data used here is four times the quarterly (Jun. 2022) net income data. The Revenue data used here is four times the quarterly (Jun. 2022) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Covetrus ROE % Related Terms

Thank you for viewing the detailed overview of Covetrus's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Covetrus (Covetrus) Business Description

Traded in Other Exchanges
N/A
Address
7 Custom House Street, Portland, ME, USA, 04101
Covetrus Inc is an animal-health technology and services company dedicated to supporting the companion, equine, and large-animal veterinary markets. Its segments are North America, Europe and the Asia Pacific (APAC) and Emerging Markets. The company's services include supply chain services, software solutions, and prescription management.
Executives
Benjamin Wolin director C/O EVERYDAY HEALTH, INC., 345 HUDSON STREET, 16TH FLOOR, NEW YORK NY 10014
Edward Mcnamara director C/O COVETRUS, INC., 7 CUSTOM HOUSE STREET, PORTLAND ME 04101
Rebecca Ann Kidd officer: Head of Global Operations 7 CUSTOM HOUSE STREET, PORTLAND ME 04101
Matthew Malenfant officer: Chief Commercial Officer 7 CUSTOM HOUSE STREET, PORTLAND ME 04101
Andrew B. Coxhead officer: See Remarks C/O RR DONNELLEY, 111 SOUTH WACKER DRIVE, CHICAGO IL 60606
Dustin Finer officer: Chief People Officer 7 CUSTOM HOUSE STREET, PORTLAND ME 04101
Paul R. Fonteyne director C/O RESTORBIO, INC., 501 BOYLSTON STREET SUITE 6102, BOSTON MA 02116
Laura J Phillips officer: See Remarks 7 CUSTOM HOUSE STREET, PORTLAND ME 04101
Michael Ellis officer: See Remarks C/O HS SPINCO, INC., 135 DURYEA ROAD, MELVILLE NY 11747
Timothy Ludlow officer: See Remarks C/O COVETRUS, INC., 7 CUSTOM HOUSE STREET, PORTLAND ME 04101
Georgina Wraight officer: See Remarks C/O COVETRUS, INC., 7 CUSTOM HOUSE STREET, PORTLAND ME 04101
David Stuart Hinton officer: See Remarks C/O HS SPINCO, INC., 135 DURYEA ROAD, MELVILLE NY 11747
Providenti Anthony C. Jr. officer: See Remarks 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Jamey S Seely officer: General Counsel and Secretary C/O GATES INDUSTRIAL CORPORATION PLC, 1144 FIFTEENTH STREET, SUITE 1400, DENVER CO 80202
Sandra E Peterson director 100 PARSONS POND DRIVE, FRANKLIN LAKES NJ 07417